The New Orleans-based Answer ALS Research Program, a consortium of medical research centers, technology companies and patients with amyotrophic lateral sclerosis, has completed phase one development of a major technology infrastructure that will enable researchers to securely collaborate on efforts to unlock the causes of ALS and develop new treatment protocols. Coordinated by Johns Hopkins and the Robert Packard Center for ALS Research, Answer ALS aims to accelerate biological analysis of the disease by leveraging opportunities in cloud computing, artificial intelligence and machine learning.
Daavlin Co., of Bryan, Ohio, is partnering with Healthlens LLC, of Los Gatos, Calif., to increase access to phototherapy in the home. The company’s Daavlindirect connects board-certified doctors with patients through an online telehealth portal powered by Healthlens for a consultation, and if phototherapy is recommended, a light therapy prescription is sent to Daavlin to fill, reducing time to treatment.
Netanya, Israel-based Eitan Group said that it has signed an agreement with Integrated Medical Systems Inc., of Alsip, Ill., making IMS a service provider for Eitan Group’s Sapphire infusion systems.
Gent, Belgium-based Feops bvba said that it has been awarded a €3.2 million (US$3.5 million) grant from the European Innovation Council accelerator program. The company’s Heartguide predictive preoperative planning system for transcatheter structural heart interventions received CE mark and Health Canada approvals earlier this year.
Genomind Inc., of King of Prussia, Pa., has formed a joint venture with Atlanta-based Sharecare Inc. aimed at improving mental health outcomes. Through partnership, Genomind’s mental health education and pharmacogenomic services will be available via Sharecare’s health and wellness engagement platform.
Limflow SA, of Paris, said the first patient has been enrolled in its PROMISE II U.S. pivotal study of the Limflow percutaneous deep vein arterialization system. The procedure was performed at Harbor-UCLA Medical Center in Los Angeles.
Boston-based Mendix Inc., a Siemens business, reported that Kermit PPI, of Lutherville, Md., is expanding its implantable medical device-focused spend-management platform for hospitals nationwide.
Ontera Inc., of Santa Cruz, Calif., and Quantumdx Group Ltd., of Newcastle Upon Tyne, England, are teaming up to create a next-generation solution for blood stream infection and drug resistance detection. The technology will build on Quantumdx’s rapid cell/sample preparation technology, called Capture-XT, and Ontera’s nanopore biosensor, which is used in its SAM and DUO Nano platforms.
New York-based Perceptive Advisors LLC said that it has closed its inaugural venture capital fund, the Perceptive Xontogeny Venture Fund LP, aimed at investing in early-stage life sciences companies. The PXV Fund was oversubscribed, closing with $210 million in global commitments.
Amsterdam-based Royal Philips NV and Orangeburg, S.C.-based Regional Medical Center have entered a $16 million, five-year strategic agreement to deliver diagnostic imaging solutions for residents in rural parts of the state. The partnership will also support expansion of the region’s only standalone community hospital, standardization of RMC’s imaging platforms and improve workflow efficiencies.
Thermogenesis Holdings Inc., of Rancho Cordova, Calif., reported that it has submitted a letter to the U.S. FDA’s design history file updating the device listing for its next-generation PXP-1000 system.
Palo Alto-based Verantos Inc. said it has received a grant from the National Institutes of Health’s National Center for Advancing Translational Sciences to support clinical phenotyping utilizing real-world evidence studies. The grant support Verantos’ efforts to define the clinical phenotype, a detailed picture of patient characteristics required for RWE studies.